Watch Demo

The Czech Republic Antihypertensive Industry Outlook 2022 - 2026

See how the Czech Republic Antihypertensive performed compared to key markets such as Germany, Italy and Spain.

Key Market Indicators

Czech sales of antihypertensive medicines are projected to reach around $37 million by 2026, up from $36 million in 2021. This represents an average annual growth rate of 0.8%. Since 1995, demand for these medicines in the Czech Republic has grown by an average of 4.9% each year. In 2021, the country was ranked tenth in the world for antihypertensive medicine sales, slightly behind Sweden, which had sales of $36 million. Italy, Spain and Australia took the second, third and fourth spots, respectively.

The Czech Republic Antihypertensive Market Data and Forecasts

How much will the Czech Republic Antihypertensive Market grow to 2026?

Forecast: Renin-Angiotensin System Medicine Sales in Czech Republic
Forecast: Renin-Angiotensin System Medicine Sales in Czech Republic
Forecast: Renin-Angiotensin System Medicine Sales in Czech Republic
Forecast: Renin-Angiotensin System Medicine Sales in Czech Republic
Forecast: Renin-Angiotensin System Medicine Sales in Czech Republic
More in Antihypertensive Industry for 2027

Improve your Knowledge with the latest Indicators and Trends